M Ventures
VC Fund
Amsterdam, The Netherlands
M Ventures is a VC fund in Amsterdam focused on Biotechnology and Health Care. Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
- Total investments:
- 188
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries M Ventures invests in
Stages M Ventures invests in
Countries M Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 24 contacts → | |||
Round size
- Seed
- $2.4M–$24M
- Series A
- $5.8M–$50M
- Series B
- $13M–$100M
Investment Focus
Industry
- Biotechnology 64 (34%)
- Health Care 41 (22%)
- Therapeutics 30 (16%)
- Medical 22 (12%)
- Pharmaceutical 15 (8%)
Stage
- Series A 64 (34%)
- Series B 37 (20%)
- Seed 29 (15%)
- Series C 14 (7%)
- Venture - Series Unknown 7 (4%)
Country
- United States 48 (26%)
- United Kingdom 14 (7%)
- Switzerland 11 (6%)
- Germany 9 (5%)
- Israel 7 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christian Patze
Associate, Performance Materials
|
Associate, Performance Materials | Total investments: 1 | Find email | |
Noga Yerushalmi
Head of Israel Bio-incubator
|
Head of Israel Bio-incubator | Total investments: 2 | Find email | |
Sarah Luppino
Associate
|
Associate | Total investments: 1 | Find email | |
Alexander Hoffmann
Principal
|
Principal | Total investments: 8 | Find email | |
Alicia Iruzun Lafitte
Principal
|
Principal | Total investments: 4 | Find email | |
| See all 24 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Polaris Electro-Optics empowers integrated photonics for communications and computation. | $50M / Series B / Sep 15, 2026 | ||
| TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors. | $62.5M / Series A / Sep 09, 2026 | ||
| Quintessent is a Santa Barbara start-up that commercializes quantum dot-based lasers and photonic integrated circuits. Its solutions leverage the unique properties of quantum dot gain media with co-designed architectures to enable future applications in optical networking, deep learning systems, and sensing.It is based in Santa Barbara,California. | $40M / Series A / Aug 24, 2026 | ||
| Remepy is biotechnology research pioneering hybrid drugs. The company believes that in the future, software applications will become an integral part of treatments offered by Pharma companies in the form of Hybrid Drugs. These will include both a software component and a traditional drug component - influencing patients via Hybrid Mechanisms ofAction™.It was founded in 2022 and is located in Ramat Gan, Tel Aviv. | $36M / Series A / Aug 12, 2026 | ||
| EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy. | $37.7M / Series C / Jul 07, 2026 | ||
| TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | ||
| Future Fertility is a fertility technology company focused on AI-enabled and non-invasive diagnostic solutions to optimize decision making throughout the IVF journey, maximizing the probability of positive outcomes in IVF workflows. The first product is an egg assessment software, which uniquely provides insights in egg quality and has thepotential to improve success rates of IVF, egg freezing and egg donation cycles. | $4.1M / Series A / Apr 23, 2026 | ||
| Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $56M / Series C / Apr 16, 2026 | ||
| Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $27M / Venture - Series Unknown / Apr 14, 2026 | ||
| ImmuneBridge is developing allogeneic immunotherapies for cancer. ImmuneBridge's key innovation fosters the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immunotherapies. They are currently looking for natural killer cell-based treatments for hematologicalcancers. They will then attack solid tumors using the special benefits of their cellular source. | $7.7M / Seed / Mar 23, 2026 | ||
| See all 188 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does M Ventures invest in?
M Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 188 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is M Ventures's check size?
M Ventures typically joins rounds of $2.4M–$24M at Seed, $5.8M–$50M at Series A and $13M–$100M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds M Ventures participates in.
How do I contact M Ventures?
Public channels for M Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at M Ventures?
The team at M Ventures includes Christian Patze (Associate, Performance Materials), Noga Yerushalmi (Head of Israel Bio-incubator) and Sarah Luppino (Associate), among 24 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
